BioPharmX completes enrollment in study of topical
Post# of 223
Posted On: 05/05/2016 7:06:26 PM
BioPharmX completes enrollment in study of topical minocycline gel to treat acne
May 5, 2016
BiopharmX Corp. recently announced in a press release that it has completed enrollment in a phase 2a study of BPX-01, a novel topical minocycline gel to treat acne.
“This research is important in the dermatology community, which has been searching for an effective alternative to current oral antibiotic acne treatments,” AnnMarie Daniels, executive vice president of clinical and regulatory affairs for BioPharmX, stated in the release. “Our preclinical tests show the potential of PBX-01, which we believe may be able to offer dermatologists a safe, effective treatment for one of the most common skin conditions in the world.”
The study will measure the safety of BPX-01 in 30 patients randomized to 30 days of treatment with either BPX-01 or a placebo, according to the release. Reduction of Propionibacterium acnes and cutaneous tolerance of the BPX-01 are primary study endpoints.
BPX-01’s topical gel formulation of minocycline is able to penetrate the epidermis, allowing delivery of the antibiotic to the dermis layer of the skin, according to nonclinical study results, the release reported.
“BPX-01 is the only stable hydrophilic topic gel with fully solubilized minocycline, the antibacterial and anti-inflammatory medicine most commonly prescribed to treat acne vulgaris,” the release reported. “It is anticipated that BPX-01 may effectively treat acne with lower, and therefor potentially safer, does of the antibiotic.”
While the FDA has found oral minocycline to be safe, the high dosage required to make an effective oral version can cause side effects, according to the release. BPX-01 could be an alternative to oral products, the release reported.
Reference: www.biopharmx.com
http://www.healio.com/dermatology/acne/news/o...treat-acne
May 5, 2016
BiopharmX Corp. recently announced in a press release that it has completed enrollment in a phase 2a study of BPX-01, a novel topical minocycline gel to treat acne.
“This research is important in the dermatology community, which has been searching for an effective alternative to current oral antibiotic acne treatments,” AnnMarie Daniels, executive vice president of clinical and regulatory affairs for BioPharmX, stated in the release. “Our preclinical tests show the potential of PBX-01, which we believe may be able to offer dermatologists a safe, effective treatment for one of the most common skin conditions in the world.”
The study will measure the safety of BPX-01 in 30 patients randomized to 30 days of treatment with either BPX-01 or a placebo, according to the release. Reduction of Propionibacterium acnes and cutaneous tolerance of the BPX-01 are primary study endpoints.
BPX-01’s topical gel formulation of minocycline is able to penetrate the epidermis, allowing delivery of the antibiotic to the dermis layer of the skin, according to nonclinical study results, the release reported.
“BPX-01 is the only stable hydrophilic topic gel with fully solubilized minocycline, the antibacterial and anti-inflammatory medicine most commonly prescribed to treat acne vulgaris,” the release reported. “It is anticipated that BPX-01 may effectively treat acne with lower, and therefor potentially safer, does of the antibiotic.”
While the FDA has found oral minocycline to be safe, the high dosage required to make an effective oral version can cause side effects, according to the release. BPX-01 could be an alternative to oral products, the release reported.
Reference: www.biopharmx.com
http://www.healio.com/dermatology/acne/news/o...treat-acne
(0)
(0)BioPharmX Corporation (BPMX) Stock Research Links
Scroll down for more posts ▼